Active immunotherapy for cancer patients using tumor lysate pulsed dendritic cell vaccine: a safety study

OVALI E., DIKMEN T., Sonmez M., YILMAZ M., UNAL A., DALBASTI T., ...Daha Fazla

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, cilt.26, sa.2, ss.209-214, 2007 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 26 Sayı: 2
  • Basım Tarihi: 2007
  • Dergi Adı: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.209-214
  • Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

Cancer vaccine therapy represents a promising therapeutical option. Consistently, with these new treatment strategies, the use of dendritic cell vaccines is becoming increasingly widespread and currently in the forefront for cancer treatment. The purpose of this study was to evaluate the feasibility and safety of tumor lysate-pulsed dendritic cell (DC) vaccine in patients with advanced cancers. For this purpose, eighteen patients with relapsed or refractory cancer were vaccinated with peripheral monocyte-derived DCs generated with GM-CSF and IL-4, and pulsed consequently with 100 mu g/ml of tumor lysate before maturation in culture in the presence of IL-1 beta, PGE(2) and TNF alpha for two days. The first two vaccinations were given intradermally every two weeks while further injections were given monthly.